Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun’s Generic Doxil Clears FDA; Janssen Uses Alternative Manufacturing Process

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval of the first generic version of Janssen’s Doxil to curtail drug’s shortage; agency also permits Janssen to use an alternative manufacturing process.

You may also be interested in...

Yesterday’s Solution; Tomorrow’s Problem

Two years ago, Sun Pharmaceuticals was a key part of FDA’s efforts in helping drug shortages; now FDA has banned imports from one of its plants.

A Victim Of Its Own Success? U-Turn On Taro Merger Could Be A Strategic Call By India’s Sun Pharma

Taro’s strong performance since Sun took a majority stake has complicated the Indian pharma’s merger plans, but analysts say the story may still evolve.

Doxil Shortage Solution: FDA Chooses Middle Ground, Allows Import Of Unapproved Version

FDA is allowing Sun Pharma Global FZE to import its unapproved liposomal version of doxorubicin, Lipodox, to alleviate a shortage, but has not yet given the drug full approval.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts